The essence of drug investment enterprises’ survival is the product, which has always been the focus of the company’s need to continuously implement targeted research. The so-called “targeted investment promotion” refers to a deep interpretation based on the company’s own situation. Adapted channels, markets, and propaganda methods to integrate superior resources to implement targeted new modes of drug investment. Its core lies in clarifying the target and channels of investment promotion, and adopting specific means to implement targeted investment promotion in specific regions under specific circumstances. Therefore, to do pharmaceutical investment, it is necessary to invest in the best products to hit the market.

First of all, the current pharmaceutical investment enterprises do not have a clear policy on product planning. In most cases, either taking a look at the few, dozens, or even hundreds of products in your hands are all good things and they all sell well. Or, they think that their products are always inferior to others. , While placing their own products can not sell well, but from other manufacturers or commercial allocation of sales. This is a big problem with such a market operation strategy. Drug investment enterprises to develop product marketing strategies, an important reference.

Second, when the pharmaceutical investment enterprise formulates a special investment promotion strategy for products, the sale of the company's own products in a certain place and the original sales of similar products in a certain place will also be an important reference for enterprises to implement product refinement and promotion. The original sales of the product are good and the market capacity is relatively large, then the star product with a company's key operation to make a certain region is available; conversely, if the product itself does not have a large sales volume in a certain place, and there are many similar products in the market, it can be considered appropriately. Take this product as the main push and seek for other incremental product operations.

Finally, various national and local systems and regulations promulgated by the pharmaceutical industry in China in the past two years are also important elements that require companies to carefully interpret and grasp the direction of development. Whether it is the introduction of the commercial bribery law, the completion of the tendering regulations, or the support of the national medical reform for the third terminal market and the improvement of the medical insurance system in the pharmaceutical system, these policies will be direct, whether promotional or normative. Affecting product investment in pharmaceutical products, companies can maintain the existing customers' markets and avoid affecting the cooperation between the two parties.